2023
Epidemiology and Pathogenesis of Myelodysplastic Syndrome
Rotter L, Shimony S, Ling K, Chen E, Shallis R, Zeidan A, Stahl M. Epidemiology and Pathogenesis of Myelodysplastic Syndrome. The Cancer Journal 2023, 29: 111-121. PMID: 37195766, DOI: 10.1097/ppo.0000000000000665.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMyelodysplastic syndromeClonal hematopoiesisMDS pathophysiologyFrank MDSOutcomes of patientsOngoing clinical trialsAcute myeloid leukemiaIndividualized therapeutic approachesRisk assessment toolVariable cytopeniasOverall incidenceUnderlying pathophysiologyClinical trialsIneffective hematopoiesisMyeloid leukemiaNovel therapiesClonal cytopeniaTherapeutic modalitiesClonal disorderTherapeutic approachesUnique molecular profileEpidemiological assessmentDisease evolutionUnknown significancePathophysiology
2018
Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it
Zeidan AM, Shallis RM, Wang R, Davidoff A, Ma X. Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. Blood Reviews 2018, 34: 1-15. PMID: 30314642, DOI: 10.1016/j.blre.2018.09.001.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCase ascertainmentAllogeneic hematopoietic stem cell transplantationAnnual age-adjusted incidenceHematopoietic stem cell transplantationOutcomes of patientsAge-adjusted incidenceStem cell transplantationAcute myeloid leukemiaTraditional morphologic assessmentClassification of MDSVariable cytopeniasCell transplantationMyelodysplastic syndromePrior receiptInefficient hematopoiesisEffective therapyMale genderRisk factorsMyeloid leukemiaEpidemiological trendsTreatment decisionsMyeloid neoplasmsEpidemiological assessmentDiagnostic criteriaTemporal improvement